Understanding how TLR5 signaling affects the immune response to tumors
TLR5 signaling as a conserved mechanism of impaired anti-tumor immunity
This study is looking at how a specific part of the immune system, which helps recognize certain bacteria, affects the body's ability to fight cancer, especially when current treatments aren't working as well as they should, and it's aimed at finding new ways to boost the immune response in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-11025902 on NIH RePORTER |
What this research studies
This research investigates how TLR5 signaling, which is involved in recognizing certain bacteria, impacts the immune system's ability to fight tumors. It focuses on the dysfunction of myeloid cells in the tumor environment and how this dysfunction can hinder the effectiveness of existing cancer therapies, particularly PD-L1 blockade. By studying animal models, the research aims to uncover new therapeutic strategies that could enhance the immune response against both primary and metastatic tumors. The goal is to identify ways to improve T cell function and overall survival in cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic cancers, particularly those who have not responded well to existing immune therapies.
Not a fit: Patients with early-stage tumors or those who have not undergone any form of immune therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance the immune system's ability to control tumor growth, potentially improving outcomes for cancer patients.
How similar studies have performed: Other research has shown promising results in enhancing immune responses through similar mechanisms, indicating that this approach may hold significant potential.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Rutkowski, Melanie R — University of Virginia
- Study coordinator: Rutkowski, Melanie R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.